Amylin Pharmaceuticals

Type	Public (NASDAQ: AMLN)
Founded	1987
Headquarters	San Diego, California, USA
Key people	Daniel M. Bradbury[1]
Industry	Biotechnology
Products	Symlin (pramlintide) Byetta (exenatide)
Employees	1,900 [1]
Website	www.amylin.com

Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company is engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces two drugs, Symlin (pramlintide acetate) and Byetta (exenatide). Amylin also is working on producing a drug based on Leptin.[2].

[edit] References